H49.81
Kearns-Sayre syndrome
Clinical Classification Guidelines
Inclusion Terms
- Progressive external ophthalmoplegia with pigmentary retinopathy
Code Also
- , if applicable, other manifestations, such as:
- heart block (I45.9)
Medical Intelligence & Overview
Kearns-Sayre Syndrome (KSS) is a rare neuromuscular disorder characterized by progressive weakness of the eye muscles (ophthalmoplegia) and pigmentary changes in the retina, which can affect vision. It typically develops in childhood or early adulthood and can involve other parts of the nervous system and organs. The condition is caused by mutations in mitochondrial DNA, leading to impaired energy production in cells. Because of its complexity and potential to involve multiple systems, understanding KSS is important for managing symptoms and monitoring health over time.
Causes & Symptoms
Clinical Causes: Mutations or deletions in mitochondrial DNA Mitochondria are responsible for generating energy in cells, and mutations impair this process The condition is inherited maternally, as mitochondria are passed from mother to child Genetic factors that lead to mitochondrial DNA mutations positive for KSS are still being researched
Key Symptoms: Progressive external ophthalmoplegia (difficulty moving the eyes, affecting vision and causing drooping eyelids) Pigmentary retinopathy (degeneration of the retina leading to vision loss) Ptosis (drooping of the eyelids) Muscle weakness and fatigue Ataxia (loss of coordination) Hearing loss Cardiac conduction defects, which can affect heart rhythm Endocrine problems such as diabetes or growth hormone deficiency CNS involvement leading to cognitive and behavioral issues
Diagnostic & Treatment
Diagnosis Path: Diagnosis of Kearns-Sayre Syndrome involves a combination of clinical findings, laboratory tests, and genetic analysis. Key methods include: - Clinical examination noting eye movement abnormalities and retinal changes - Electrodiagnostic tests (such as electromyography) to assess muscle function - Ophthalmologic evaluations including retinal imaging - Blood tests to identify elevated levels of specific enzymes - Muscle biopsy to observe mitochondrial abnormalities - Genetic testing to detect mitochondrial DNA deletions Because symptoms can overlap with other neuromuscular conditions, comprehensive assessment by healthcare professionals experienced with mitochondrial disorders is essential.
Treatment Protocols: There is currently no cure for Kearns-Sayre Syndrome. Management focuses on alleviating symptoms and preventing complications. Common approaches include: - Regular cardiac monitoring to detect and treat conduction abnormalities, sometimes requiring pacemaker implantation - Use of vitamin and supplement therapies like Coenzyme Q10,B Vitamins, which may support mitochondrial function - Vision correction and supportive therapies for eye movement and retinal issues - Physical therapy to maintain muscle strength and mobility - Audiological services for hearing loss - Endocrine treatments if hormonal deficiencies are present - Multidisciplinary care involving neurologists, cardiologists, ophthalmologists, and other specialists to address various organ involvements Research into treatments targeting mitochondrial function is ongoing, but current strategies mainly aim to improve quality of life and manage specific symptoms.
Clinical Advice & FAQs
Billing Guidance
Is H49.81 a billable ICD-10 code?
Yes, H49.81 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report H49.81?
Clinical documentation must specify the nature of Kearns-Sayre syndrome and any associated comorbidities for accurate reporting.
Cite this Clinical Reference
